Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Genmab A/SNASDAQ: GMAB

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin grows 42.4% year over year

Q2 FY2026 selling, general & admin of $205M rose 42.4% year over year. Sequentially, it rose 23.0% from the prior quarter. Over 3 fiscal years it compounded at -39.2% a year.

Context

  • Selling, general & admin amounted to 16.2% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 15 analysts of $762.51M (+26.6%) for the fiscal year ending Dec 2026, a step up from the -84.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$205M+23.0% QoQ
Last fiscal yearDec 2025
$602.47M-84.1% YoY
LTMJun 2026
$726.99M— YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.4%+36.9%-5.5 pp
1 year-84.1%+26.6%+110.7 pp
3-year CAGR-39.2%+21.6%+60.8 pp
5-year CAGR+13.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

Mixed currencies · from the income statement

Latest · FY2025
602.47M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Selling, general & admin amounts to 17.6% of revenue for GMAB, versus a peer median of 26.3%.
GMAB Competitors
Selling, General & Admin for GMAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.4B USD+8.2%+11.2%24.0%
BNTXBioNTech SELTM Jun 2026€788.8M EUR+45.9%+8.9%29.8%
GMABGenmab A/SLTM Jun 2026$726.99M USD—-39.2%17.6%
EXELExelixis, Inc.LTM Jul 2026$533.92M USD+3.0%+4.1%21.9%
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M USD+10.5%+25.2%26.3%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$153.2M USD-3.3%+13.5%40.4%
RCUSArcus Biosciences, Inc.LTM Jun 2026$106M USD-7.8%+1.9%90.6%
ADCTADC Therapeutics S.A.LTM Mar 2026$82.03M USD+32.5%—103.6%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M USD-23.4%-6.3%—
CGENCompugen Ltd.LTM Mar 2026$9.36M USD-6.3%-5.7%12.9%
Peer median (excluding GMAB) —-0.1%+4.1%26.3%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Revenue8.42B14.51B16.47B21.53B3.72B
Cost of Revenue00226M985M309.24M
Gross Profit8.42B14.51B16.25B20.54B3.41B
Gross Margin100.0%100.0%98.6%95.4%91.7%
Research & Development4.18B5.56B7.63B9.75B1.56B
Selling, General & Admin1.28B2.68B3.3B3.79B602.47M
Operating Expenses5.46B8.24B10.93B13.84B2.16B
Depreciation & Amortization248.99M362M293.62M413M71.06M
EBITDA4.18B7.35B6B9.7B1.34B
EBITDA Margin49.7%50.6%36.4%45.0%35.9%
Operating Income2.95B6.27B5.32B6.7B1.25B
Operating Margin35.1%43.2%32.3%31.1%33.6%
Interest Income197M324M939M995M138.11M
Interest Expense13M21M27M120M61.05M
Other Income / Expenses965M678M316M2.46B(46.04M)
Income Before Tax3.92B6.95B5.64B9.16B1.2B
Pre-Tax Margin46.5%47.9%34.2%42.6%32.4%
Income Tax Expense961M1.49B1.29B1.32B241.19M
Net Income2.96B5.45B4.35B7.84B963.76M
Net Margin35.1%37.6%26.4%36.4%25.9%
EPS (Basic)4.528.346.6012.141.55
EPS (Diluted)4.488.266.6012.141.54
Weighted Avg Shares653.96M653.87M659.15M646.33M621.51M
Weighted Avg Shares (Diluted)660.46M660.1M659.15M646.33M626.92M

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.